Sana Biotechnology (NASDAQ:SANA) Stock Price Up 7.4% on Analyst Upgrade

Sana Biotechnology, Inc. (NASDAQ:SANA)’s stock price traded up 7.4% during mid-day trading on Tuesday after Bank of America raised their price target on the stock from $6.00 to $7.00. Bank of America currently has a buy rating on the stock. Sana Biotechnology traded as high as $4.46 and last traded at $4.3620. 634,615 shares traded hands during trading, a decline of 57% from the average session volume of 1,475,205 shares. The stock had previously closed at $4.06.

Several other equities research analysts have also recently weighed in on SANA. JMP Securities set a $8.00 price target on Sana Biotechnology in a research report on Thursday, October 30th. HC Wainwright reduced their price objective on shares of Sana Biotechnology from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Wedbush increased their target price on shares of Sana Biotechnology from $5.00 to $6.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. Citigroup reissued an “outperform” rating on shares of Sana Biotechnology in a report on Thursday, October 30th. Finally, Citizens Jmp upped their price target on shares of Sana Biotechnology from $5.00 to $8.00 and gave the stock a “market outperform” rating in a report on Thursday, October 30th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Sana Biotechnology currently has an average rating of “Moderate Buy” and a consensus target price of $8.14.

Hedge Funds Weigh In On Sana Biotechnology

Large investors have recently added to or reduced their stakes in the business. Baillie Gifford & Co. boosted its position in Sana Biotechnology by 13.6% during the third quarter. Baillie Gifford & Co. now owns 11,436,503 shares of the company’s stock valued at $40,600,000 after buying an additional 1,371,775 shares during the period. Vanguard Group Inc. grew its position in Sana Biotechnology by 19.9% during the 3rd quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company’s stock worth $32,408,000 after acquiring an additional 1,517,474 shares during the last quarter. Marex Group plc purchased a new position in Sana Biotechnology in the 2nd quarter worth approximately $10,423,000. JPMorgan Chase & Co. increased its stake in Sana Biotechnology by 180.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company’s stock worth $7,581,000 after purchasing an additional 1,375,029 shares during the period. Finally, Integral Health Asset Management LLC lifted its position in Sana Biotechnology by 33.3% in the third quarter. Integral Health Asset Management LLC now owns 2,000,000 shares of the company’s stock valued at $7,100,000 after purchasing an additional 500,000 shares during the last quarter. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Price Performance

The stock has a market cap of $1.26 billion, a PE ratio of -4.88 and a beta of 1.96. The business has a 50 day moving average price of $4.28 and a two-hundred day moving average price of $3.99.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.03. On average, sell-side analysts forecast that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.